51
|
Tang L, He S, Zhu Y, Feng B, Su Z, Liu B, Xu F, Wang X, Liu H, Li C, Zhao J, Zheng X, Li C, Sun C, Lu C, Zheng G. Downregulated miR-187 contributes to the keratinocytes hyperproliferation in psoriasis. J Cell Physiol 2018; 234:3661-3674. [PMID: 30607907 DOI: 10.1002/jcp.27135] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 07/05/2018] [Indexed: 01/08/2023]
Abstract
Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation. However, the pathogenesis of psoriasis is multifactorial and is not fully understood. MicroRNAs (miRNAs) represent a promising class of small, noncoding RNA molecules that have a large impact on cellular functions by regulating gene expression. Here we reported that microRNA-187 (miR-187), which is one of the most dynamic microRNAs identified in the deep screening miRNAs profile, is downregulated in inflammatory cytokines-stimulated keratinocytes and psoriatic skins. By luciferase activity assay and gain-of-function studies, we showed that miR-187 inhibits keratinocytes hyperproliferation by targeting CD276. Moreover, overexpression of miR-187 decreases acanthosis and reduces the disease severity in psoriasis mouse models. Taken together, the results of our study implies miR-187 as a critical factor in psoriasis pathogenesis, which could be a potent target for psoriasis treatment.
Collapse
Affiliation(s)
- Lipeng Tang
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.,The Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Songmin He
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Ying Zhu
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Bing Feng
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Zuqing Su
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Bo Liu
- Department of Chemical Research and Structural Optimization based on Chinese Material Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Fangfang Xu
- Department of Chemical Research and Structural Optimization based on Chinese Material Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Xieqi Wang
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Hongying Liu
- Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Chutian Li
- Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Jie Zhao
- Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Xirun Zheng
- Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Caiyun Li
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Chaoyue Sun
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Chuanjian Lu
- Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Guangjuan Zheng
- Deparment of Pharmacology of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.,Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| |
Collapse
|
52
|
Zuo J, Wang B, Long M, Gao Z, Zhang Z, Wang H, Wang X, Li R, Dong K, Zhang H. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to promote malignancy and glycolysis in HeLa cells. FEBS Lett 2018; 592:2476-2488. [PMID: 29924389 DOI: 10.1002/1873-3468.13164] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Revised: 05/28/2018] [Accepted: 06/06/2018] [Indexed: 12/19/2022]
Abstract
The role of the type 1 transmembrane glycoprotein B7-H3 is controversial in tumorigenesis; thus, a better clarification of its involvement in cancer is crucial. In the present study, 79.3% of cervical cancer samples were found to be B7-H3 positive and the expression of B7-H3 was positively correlated with the clinical features of the samples. Silencing B7-H3 using small interfering RNA or blocking it with intracellular ScFv attenuated the malignancy of HeLa cells. By pull-down assay and liquid chromatography-mass spectrometry in HeLa cells, the glycolytic enzyme ENO1 was found to interact with B7-H3. Subsequently, the involvement of B7-H3 in glycolysis was investigated. We observed decreases in the levels of ATP and lactate, as well as c-Myc and lactate dehydrogenase A, upon B7-H3 downregulation in HeLa cells. The results of the present study provide evidence for B7-H3 mediating tumor glycolysis.
Collapse
Affiliation(s)
- Jiahui Zuo
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Bowen Wang
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Min Long
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Zhaowei Gao
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Zhe Zhang
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Huiping Wang
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Xi Wang
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Ruicheng Li
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Ke Dong
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| | - Huizhong Zhang
- Department of Medicine Laboratory and Research Center, The Second Affiliated Hospital of Air Force Medical University, Air Force Medical University, Xi'an, Shanxi, China
| |
Collapse
|
53
|
Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 As a Promoter of Metastasis and Promising Therapeutic Target. Front Oncol 2018; 8:264. [PMID: 30035102 PMCID: PMC6043641 DOI: 10.3389/fonc.2018.00264] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 06/26/2018] [Indexed: 12/12/2022] Open
Abstract
B7H3 (also known as CD276, an immune checkpoint molecule) is aberrantly overexpressed in many types of cancer, and such upregulation is generally associated with a poor clinical prognosis. Recent discoveries indicate a crucial role for B7H3 in promoting carcinogenesis and metastasis. This review will focus on the latest developments relating specifically to the oncogenic activity of B7H3 and will describe the upstream regulators and downstream effectors of B7H3 in cancer. Finally, we discuss the emerging roles of microRNAs (miRNAs) in inhibiting B7H3-mediated tumor promotion. Excellent recent studies have shed new light on the functions of B7H3 in cancer and identified B7H3 as a critical promoter of tumor cell proliferation, migration, invasion, epithelial-to-mesenchymal transition, cancer stemness, drug resistance, and the Warburg effect. Numerous miRNAs are reported to regulate the expression of B7H3. Our meta-analysis of miRNA database revealed that 17 common miRNAs potentially interact with B7H3 mRNA. The analysis of the TCGA ovarian cancer dataset indicated that low miR-187 and miR-489 expression was associated with poor prognosis. Future studies aimed at delineating the precise cellular and molecular mechanisms underpinning B7H3-mediated tumor promotion will provide further insights into the cell biology of tumor development. In addition, inhibition of B7H3 signaling, to be used alone or in combination with other treatments, will contribute to improvements in clinical practice and benefit cancer patients.
Collapse
Affiliation(s)
- Peixin Dong
- Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan
| | - Ying Xiong
- Department of Gynecology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Junming Yue
- Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.,Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, United States
| | - Sharon J B Hanley
- Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hidemichi Watari
- Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan
| |
Collapse
|
54
|
Cheng R, Chen Y, Zhou H, Wang B, Du Q, Chen Y. B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. APMIS 2018; 126:396-402. [PMID: 29696716 DOI: 10.1111/apm.12837] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Accepted: 03/13/2018] [Indexed: 01/10/2023]
Abstract
This study was designed to explore the expression of B7-H3 in human intrahepatic cholangiocarcinoma (ICC) and its association with the clinicopathologic factors. In the current study, the expression of B7-H3 in 45 patients with intrahepatic cholangiocarcinoma and 8 patients with hepatolithiasis was analyzed by immunohistochemistry, which revealed that B7-H3 was not expressed in hepatolithiatic tissues, but positively expressed in 57.8% (26/45) of the ICC cases. The expression of B7-H3 was significantly associated with lymph node metastases and venous invasion. A positive correlation was also observed between the expression of B7-H3 and MVD, an index for tumor angiogenesis. Further survival analysis indicated that patients with B7-H3 negative expression had higher overall survival (OS) and cancer-specific survival (CSS) rates than those with B7-H3 positive expression. Multivariate analysis revealed that B7-H3 expression was an independent prognostic indicator for poor OS and CSS of ICC patients. Our results suggest that B7-H3 may be a valuable biomarker in determining tumor progression and prognosis of intrahepatic cholangiocarcinoma. It is also a potential target for antivascular therapy of ICC.
Collapse
Affiliation(s)
- Rui Cheng
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Yongqin Chen
- Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Haohui Zhou
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Bi Wang
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Qiang Du
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Yanling Chen
- Department of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| |
Collapse
|
55
|
Wen L, Wen YC, Ke GJ, Sun SQ, Dong K, Wang L, Liao RF. TRPV4 regulates migration and tube formation of human retinal capillary endothelial cells. BMC Ophthalmol 2018; 18:38. [PMID: 29433476 PMCID: PMC5809855 DOI: 10.1186/s12886-018-0697-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 01/29/2018] [Indexed: 02/03/2023] Open
Abstract
Background Ca2+ entry plays an important role in modulating endothelial cell migration and tube formation. Transient receptor potential cation channel subfamily V member 4 (TRPV4) is a Ca2+-permeable channel that is widely expressed in endothelial cells. It has been reported that TRPV4 is expressed in HRCECs and regulates Ca2+ entry. However, the function of TRPV4 in human retinal capillary endothelial cells (HRCECs) remains unknown. Methods In this study we used western blot and immunostaining assay to verify TRPV4 expression in HRCECs. And then we pretreated HRCECs with HC067047 and transfected with specific shRNA of TRPV4. The functional presence of TrpV4 was determined by using fluorescence, migration and tube formation assay in TrpV4 knockdown cells or control cells. Results Using western blot and immunostaining, we confirmed TRPV4 expression in HRCECs. Moreover, inhibition of TRPV4 using the specific inhibitor HC067047 and the knockdown of TRPV4 with shRNA significantly suppressed tube formation and migration by HRCECs. Conclusions TRPV4 is essential for HRCEC migration and tube formation, and maybe a potential therapeutic target for retinal vascular diseases. Electronic supplementary material The online version of this article (10.1186/s12886-018-0697-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Lei Wen
- Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui, 230022, China.,Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Yue-Chun Wen
- Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Gen-Jie Ke
- Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Si-Qin Sun
- Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Kai Dong
- Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Lin Wang
- Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
| | - Rong-Feng Liao
- Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, Anhui, 230022, China.
| |
Collapse
|
56
|
Li G, Quan Y, Che F, Wang L. B7-H3 in tumors: friend or foe for tumor immunity? Cancer Chemother Pharmacol 2018; 81:245-253. [PMID: 29299639 DOI: 10.1007/s00280-017-3508-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 12/21/2017] [Indexed: 12/11/2022]
Abstract
B7-H3 is a type I transmembrane co-stimulatory molecule of the B7 family. B7-H3 mRNA is widely distributed in most tissues; however, B7-H3 protein is not constitutively expressed. Few molecules have been shown to mediate the regulation of B7-H3 expression, and their regulatory mechanisms remain unexplored. Recently, TREM-like transcript 2 (TLT-2) has been identified as a potential receptor of B7-H3. However, TLT-2 may not be the only receptor of B7-H3, as B7-H3 has many contradictory roles. As a co-stimulatory molecule, B7-H3 increases the proliferation of both CD4+ and CD8+ T-cells and enhances cytotoxic T-cell activity. However, greatly increased T-cell proliferation and IL-2 levels have been observed in the absence of B7-H3. Thus far, it has been shown that various tumors test positive for B7-H3 expression and that B7-H3 levels correlate with tumor growth, invasion, metastasis, malignant stage, and recurrence rate. Furthermore, transfection of cells with a B7-H3 plasmid and treatment with monoclonal antibodies to block B7-H3 are the main immunotherapeutic strategies for cancer treatment. Several groups have generated anti-B7-H3 antibodies and observed tumor growth suppression in vitro and in vivo. Therefore, it is likely that B7-H3 plays an important role in cancer diagnosis and treatment, aside from its role as a co-stimulatory molecule.
Collapse
Affiliation(s)
- Gen Li
- Department of Neurology, Clinical Medicine College, Weifang Medical University, No. 7166, Baotong West Street, Weifang city, Shandong Province, 261053, China.,Central Laboratory, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China
| | - Yanchun Quan
- Central Laboratory, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China
| | - Fengyuan Che
- Central Laboratory, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China. .,Department of Neurology, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China.
| | - Lijuan Wang
- Central Laboratory, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China. .,Department of Hematology, Linyi People's Hospital, Shandong University, NB27, Eastern Part of Jiefang Road, Lanshan District, Linyi city, Shandong Province, 276000, China.
| |
Collapse
|
57
|
Borrie AE, Maleki Vareki S. T Lymphocyte–Based Cancer Immunotherapeutics. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 2018; 341:201-276. [DOI: 10.1016/bs.ircmb.2018.05.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
58
|
Marcucci F, Rumio C, Corti A. Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. Biochim Biophys Acta Rev Cancer 2017; 1868:571-583. [PMID: 29056539 DOI: 10.1016/j.bbcan.2017.10.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 10/17/2017] [Accepted: 10/18/2017] [Indexed: 02/06/2023]
Abstract
Inhibitory or stimulatory immune checkpoint molecules are expressed on a sizeable fraction of tumor cells in different tumor types. It was thought that the main function of tumor cell-associated immune checkpoint molecules would be the modulation (down- or upregulation) of antitumor immune responses. In recent years, however, it has become clear that the expression of immune checkpoint molecules on tumor cells has important consequences on the biology of the tumor cells themselves. In particular, a causal relationship between the expression of these molecules and the acquisition of malignant traits has been demonstrated. Thus, immune checkpoint molecules have been shown to promote the epithelial-mesenchymal transition of tumor cells, the acquisition of tumor-initiating potential and resistance to apoptosis and antitumor drugs, as well as the propensity to disseminate and metastasize. Herein, we review this evidence, with a main focus on PD-L1, the most intensively investigated tumor cell-associated immune checkpoint molecule and for which most information is available. Then, we discuss more concisely other tumor cell-associated immune checkpoint molecules that have also been shown to induce the acquisition of malignant traits, such as PD-1, B7-H3, B7-H4, Tim-3, CD70, CD28, CD137, CD40 and CD47. Open questions in this field as well as some therapeutic approaches that can be derived from this knowledge, are also addressed.
Collapse
Affiliation(s)
- Fabrizio Marcucci
- Department of Pharmacological and Biomolecular Sciences, University of Milan, via Trentacoste 2, Milan, Italy.
| | - Cristiano Rumio
- Department of Pharmacological and Biomolecular Sciences, University of Milan, via Trentacoste 2, Milan, Italy.
| | - Angelo Corti
- Vita-Salute San Raffaele University, DIBIT-Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, Milan, Italy.
| |
Collapse
|